Hendrik Peter Scholl
Known title: Chief Medical OfficerCIK: 0002113223
Associated companies
Transaction History
| BLTE | ▼ Sell | Open Market | 200 | $33K | 10/1/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 24 | $4K | 10/1/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 120 | $20K | 10/1/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 50 | $8K | 10/1/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 78 | $13K | 10/1/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 12 | $2K | 10/1/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 14 | $2K | 10/1/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 2 | $340 | 10/1/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 96 | $14K | 6/18/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 3,748 | $542K | 6/18/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 4,861 | $707K | 6/18/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 1,199 | $175K | 6/18/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 96 | $14K | 6/18/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 540 | $76K | 6/16/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 2,054 | $283K | 6/16/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 784 | $108K | 6/16/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 3,140 | $438K | 6/16/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 100 | $14K | 6/16/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 450 | $64K | 6/16/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 1,897 | $272K | 6/16/2026 | View on chart |
| BLTE | ▼ Sell | Open Market | 1,035 | $150K | 6/16/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLTE to Deliver Oral Presentations at Two Medical Conferences
Belite Bio announced that it will give oral presentations at two upcoming medical conferences. The company plans to share data on its pipeline during these sessions. The news arrives as the stock is trading near a long‑standing support level around $153.70, a point that has been tested many times. Investors may watch the conferences for updates that could affect perception of the company's progress.
BLTE to Deliver Oral Presentations at Two Medical Conferences. Belite Bio announced that it will give oral presentations at two upcoming medical conferences. The company plans to share data on its pipeline during these sessions. The news arrives as the stock is trading near a long‑standing support level around $153.70, a point that has been tested many times. Investors may watch the conferences for updates that could affect perception of the company's progress.